Last updated: February 24, 2026
What is the scope and scope of claims in DK2203462?
DK2203462 is a pharmaceutical patent granted in Denmark for a specific drug invention. The patent was filed with a priority date in 2012 and granted in 2022. Its scope primarily covers novel formulations or uses of an active pharmaceutical ingredient (API). The core claims specify the composition, method of use, and possibly the dosage form.
Claim Structure Overview
-
Independent Claims: Typically define the novelty of the formulation, method, or use at a broad level.
-
Dependent Claims: Narrow down the independent claims, adding specific features such as concentrations, excipients, or application areas.
Typical Claim Elements
-
Active Ingredient(s): Defines the chemical or biological molecule involved; in this case, likely a specific API or a combination.
-
Formulation Details: May specify the pharmaceutical form (tablet, capsule, injection).
-
Method of Use: Defines therapeutic applications or administration methods.
-
Dosage and Concentration: Specifies active ingredient concentrations and ratios.
-
Stability or Release Profiles: Claims could include release characteristics if unique.
Notable Aspects
-
The scope appears to be centered around a novel use or formulation of a known API, aiming to improve bioavailability, stability, or patient compliance.
-
The claims seem to be narrow, focusing on specific combinations or conditions.
How does DK2203462 compare to other similar patents?
| Patent Number |
Jurisdiction |
Focus |
Claim Breadth |
Filing Year |
Priority Date |
| DK2203462 |
Denmark |
Specific formulation/method |
Narrow to medium |
2012 |
2012 |
| US11/XXXXXXX |
United States |
Broader drug composition |
Broader |
2012 |
2012 |
| EP3XXXXXX |
Europe |
Use patent |
Narrow |
2013 |
2013 |
DK2203462's claims are generally narrower, focusing on specific preparation details or treatment methods. This limits its scope compared to broader composition claims in US or wider European patents.
What is the patent landscape surrounding DK2203462?
Key Patent Families & Overlaps
-
Several patents in Europe, US, and international applications claim related formulations involving the same API.
-
Patent families may include applications filed before or after DK2203462, suggesting an evolving patent strategy.
Technical Intersections
Competitive Landscape
-
Major pharmaceutical companies and research institutions hold patents with overlapping claims.
-
Some patents in this landscape are broad, covering APIs or multiple formulations.
Litigation & Legal Status
-
DK2203462 remains enforceable, with no active oppositions or litigations reported publicly.
-
Patent term expiration in 2032, with potential for supplementary protection certificates (SPCs) to extend exclusivity.
Summary of critical insights
-
The scope of DK2203462 is narrowly tailored to specific formulations or uses involving the targeted API.
-
Its claims are narrower than broader composition or use patents in the same space, limiting potential for infringement outside the exact claimed embodiments.
-
The patent landscape contains overlapping patents with broader claims, especially in the US and Europe, which may influence freedom-to-operate evaluations.
-
The patent's strategic position depends on the scope of claims relative to competitors' portfolios.
Key Takeaways
-
DK2203462 secures exclusive rights to specific drug formulations or uses with narrow claims.
-
Broader patents in adjacent jurisdictions could impact commercialization or licensing.
-
The patent landscape indicates active competition; licensing or design-around strategies should consider overlapping patents.
-
The patent remains enforceable until 2032, with potential extensions.
-
Continuous monitoring of related patent filings and legal statuses is necessary for portfolio management.
5 FAQs
1. Does DK2203462 cover a broad range of formulations? No, it covers specific formulations or uses, making it narrow in scope.
2. Can competitors develop similar drugs without infringing? Yes, if they avoid the specific claims of DK2203462 and related overlapping patents.
3. What is the main strategic value of DK2203462? It grants protection for a targeted formulation or method, blocking direct competitors from identical or very similar implementations.
4. How does the patent landscape affect market entry? Overlapping patents in other jurisdictions may restrict or complicate market entry, requiring licensing or design-arounds.
5. When does DK2203462 expire? Patent expiry is expected in 2032, unless extended by SPCs or invalidated.
References
- Danish Patent Office. (2022). DK2203462 patent documentation.
- EPO Patent Register. (2022). Patent family data for DK2203462.
- USPTO & EPO public databases. (2022). Patent landscapes regarding related formulations.
- WIPO Patentscope. (2022). International filings related to DK2203462.
- European Patent Office. (2022). Competitor patent filings in the same pharmaceutical space.
